Legal & General Group Plc Makes New $1.67 Million Investment in Enliven Therapeutics, Inc. $ELVN

Legal & General Group Plc bought a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 32,924 shares of the company’s stock, valued at approximately $1,671,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV bought a new position in Enliven Therapeutics during the first quarter valued at about $38,000. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter valued at about $83,000. Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of Enliven Therapeutics during the 2nd quarter valued at approximately $96,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ELVN shares. The Goldman Sachs Group raised their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JonesTrading increased their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. HC Wainwright raised their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, Barclays initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director directly owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 186,849 shares of company stock valued at $10,998,857. Corporate insiders own 3.00% of the company’s stock.

Enliven Therapeutics Stock Performance

ELVN opened at $59.32 on Monday. The company has a 50 day moving average of $55.66 and a 200 day moving average of $44.31. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The company has a market cap of $4.35 billion, a PE ratio of -35.52 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Research analysts forecast that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.